Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Galena Biopharma Inc.
Current Parent Company: SELLAS Life Sciences Group
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $7,550,000
Year: 2017
Date: September 8, 2017
Offense Group: government-contracting-related offenses
Primary Offense: False Claims Act and related
Secondary Offense: kickbacks and bribery
Violation Description: Galena Biopharma Inc. agreed to pay more than $7.55 million to resolve allegations that it paid kickbacks to doctors to induce them to prescribe its fentanyl-based drug Abstral. The allegations arose from a whistleblower suit filed under the False Claims Act.
Level of Government: federal
Action Type: agency action
Agency: U.S. Attorney-District of New Jersey
Civil or Criminal Case: civil
HQ Country of Current Parent: USA
HQ State of Current Parent: New York
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.